Vaccine Novavax, Ema: “Idea over pandemic limits membership”

Vaccine Novavax, “Current adherence to this vaccine appears to be limited, due to the perception that the pandemic is fading.” This fear was expressed by Marco Cavaleri, Head of Vaccines and Covid-19 Therapeutic Products of the European Medicines Agency EMA, today during the periodic briefing with the press. “And instead – objected the expert – it is of the utmost importance that anyone who has not yet taken any dose takes the opportunity to get vaccinated as soon as possible, taking into account the broadest portfolio of options that is now available”. “The Novavax Nuvaxovid Covid vaccine has been launched in Europe in recent weeks and over 3.7 million doses have been distributed to date according to the ECDC”, European Center for Disease Prevention and Control.